One of the main challenges is the lack of efficacy of the anti-Her2 agents in the intracranial disease because IV Trastuzumab has little to no penetration through the BBB (25–50% of cases will develop brain metastases and 6–7% will develop LM). Here, ERBB2 is linked to lymphangioma.